SKI II
SKI-II is an oral active and synthetic inhibitor of sphingosine kinase (SK) activity, with IC50 values of 78 μM and 45 μM for SK1 and for SK2, respectively. SKI II causes an irreversible inhibition of SK1 by inducing its lysosomal and/or proteasomal degradation[1][2].
Product Specifications
CAS Number
312636-16-1
UNSPSC
12352005
Hazard Statement
H302
Target
Apoptosis; SphK; Wnt
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/SKI-II.html
Purity
99.25
Solubility
DMSO : ≥ 100 mg/mL
Smiles
OC1=CC=C(NC2=NC(C3=CC=C(Cl)C=C3)=CS2)C=C1
Molecular Formula
C15H11ClN2OS
Molecular Weight
302.78
Precautions
H302
References & Citations
[1]Liu H, et al. SphK1 inhibitor SKI II inhibits the proliferation of human hepatoma HepG2 cells via the Wnt5A/β-catenin signaling pathway. Life Sci. 2016 Apr 15;151:23-9.|[2]Liu Y, et al. SKI-II reverses the chemoresistance of SGC7901/DDP gastric cancer cells. Oncol Lett. 2014 Jul;8 (1) :367-373.|[3]Potì F, et al. SKI-II--a sphingosine kinase 1 inhibitor--exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet. Atherosclerosis. 2015 May;240 (1) :212-5.|[4]French KJ, et al. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther. 2006 Aug;318 (2) :596-603.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
RR200636L4V 200 µL
LOC314140 (NM_001009694) Rat Tagged ORF Clone Lentiviral Particle
Sign In for Pricing
View Details 
M2871-60-ML490 100 µL
MELK (Maternal Embryonic Leucine Zipper Kinase, hMELK, HPK38, KIAA0175, pEg3 Kinase, Protein Kinase PK38, RP11-8N6.1) (MaxLight 490) discontinued
Sign In for Pricing
View Details